| Proposal number
|
Sponsor/Funder
|
Title
|
Lead researcher
|
|
|
631
|
GSK
|
Predictors of BPH Progression
|
Dr. Stephen Freedland, MD
|
Further Details
|
|
647
|
GSK
|
Assessing and Reporting Heterogeneity of Treatment Effect in Randomized Clinical Trials
|
David M. Kent, MD, MSc
|
Further Details
|
|
651
|
GSK
|
Descriptive evaluation of SAE reporting rates in vaccine clinical trials among Latin American children.
|
Thomas Verstraeten
|
Further Details
|
|
669
|
GSK
|
A multi-center, double-blind, placebo controlled study of paroxetine and imipramine in adolescents with unipolar major depression - efficacy and adverse outcomes.
|
Jon Jureidini
|
Further Details
|
|
674
|
GSK
|
Antiepileptic drug monotherapy for epilepsy: an overview of systematic reviews and
network meta-analysis
|
Antony Marson
|
Further Details
|
|
911
|
GSK
|
Outcome Measures in Systemic Lupus Erythematosus: Constructing a Meaningful Response Index from Existing Clinical Trial Data
|
Lindsy Forbess, MD, MSc
|
Further Details
|
|
930
|
GSK
|
MASTERMIND: Stratification of glycaemic response the ADOPT and RECORD studies
|
Professor Andrew Hattersley, M.D. FRS
|
Further Details
|
|
945
|
ViiV
|
THE CD4/CD8 RATIO AS A PREDICTOR OF NON-AIDS EVENTS DURING ANTIRRETROVIRAL THERAPY: CONFIRMATION OF ITS PREDICTIVE VALUE AND IMPACT OF MARAVIROC IN TREATMENT-EXPERIENCED PATIENTS
|
Santiago Moreno
|
Further Details
|
|
946
|
GSK, Roche
|
Assessing models for changes in tumour size over time and how they relate to survival times.
|
Raluca Eftimie
|
Further Details
|
|
977
|
GSK
|
The implication of central adjudication of COPD exacerbations by experts for treatment effect estimates and sample size calculation
|
Milo Puhan
|
Further Details
|
Just a moment, the page is loading...